Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry

Medical Science Monitor

Volumn 16, Issue 9, 2010, Pages

  Kałuzna Czaplińska, Joanna ^a   Socha, Ewa ^a   Rynkowski, Jacek ^a  

^a LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Autism; GC MS; Homovanillic acid; Vanillylmandelic acid

Indexed keywords

CREATININE; HOMOVANILLIC ACID; VANILMANDELIC ACID;

ANALYTIC METHOD; ARTICLE; AUTISM; CAPILLARY GAS CHROMATOGRAPHY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; URINALYSIS; URINE LEVEL; CASE CONTROL STUDY; PRESCHOOL CHILD; URINE;

AUTISTIC DISORDER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HOMOVANILLIC ACID; HUMANS; VANILMANDELIC ACID;

EID: 77957948630     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bara BG, Bucciarelli M, Colle L: Communicative abilities in autism: evidence for attentional deficits. Brain Lang, 2001; 77(2): 216-240
2. Happé F: Autism: cognitive deficit or cognitive style? Trends Cogn Sci, 1999; 3(6): 216-222
3. Newschaffer CJ, Curran LK: Autism: an emerging public health problem. Public Health Rep, 2003; 118(5): 393-399
4. Manning-Courtney P, Brown J, Molloy CA et al: Diagnosis and treatment of autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care, 2003; 33(9): 283-304
5. Lam KS, Aman MG, Arnold LE: Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil, 2006; 27(3): 254-289
6. Previc FH: Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Med Hypotheses, 2007; 68(1): 46-60
7. Hérault J, Petit E, Martineau J et al: Serotonin and autism: biochemical and molecular biology features. Psychiatry Res, 1996; 65(1): 33-43
8. London EA, Etzel RA: The environment as an etiologic factor in autism: a new direction for research. Environ Health Perspect, 2000; 108: 401-404
9. Barnea-Goraly N, Kwon H, Menon V et al: White matter structure in autism: preliminary evidence from diffusion tensor imaging. Biol sychiatry, 2004; 55(3): 323-326
10. Kałuzna-Czaplińska J, Grys W, Rynkowski J: Neurotoxic factors in the child's environment as a reason for developmental disorders in autism. Nowa Pediatria, 2008; 3: 50-57
11. Kałuzna-Czaplińska J, Grys W, Rynkowski J, Szymańska A: Role of oxidative stress in Autism. Nowa Pediatria, 2008; 4: 67-70
12. Shaw W: Biological treatments for Autism and PDD. 3rd ed. by William Shaw USA; 2008
13. Eisenhofer G, Kopin IJ, Goldstein DS: Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacol Rev, 2004; 56: 331-349
14. Madras BK, Miller GM, Fischman AJ: The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res, 2002; 130: 57-63
15. Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry, 2005; 57(11): 1397-1409
16. Baldwin CM, Bootzin RR, Schwenke DC, Quan SF: Antioxidant nutrient intake and supplements as potential moderators of cognitive decline and cardiovascular disease in obstructive sleep apnea. Sleep Med Rev, 2005; 9(6): 459-476
17. Hattori S, Hashitani T, Matsui N, Nishino H: Dynamic regulation of striatal dopaminergic grafts during locomotor activity. Brain Res, 1996; 710(1-2): 45-55
18. Nelson R: Neurochemical imbalances linked to sleep disorders. The Lancet, 2003; 362: 136
19. Anand A, Verhoeff P, Seneca N et al: Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry, 2000; 157(7): 1108-1114
20. Chou IC, Wan L, Liu SC et al: Association of the Slit and Trk-like 1 gene in Taiwanese patients with Tourette syndrome. Pediatr Neurol, 2007; 37(6): 404-406
21. Previc FH: Dopamine and the origins of human intelligence. Brain Cogn, 1999; 41(3): 299-350
22. Ungless MA: Dopamine: the salient issue. Trends Neurosci, 2004; 27(12): 702-706
23. Wieselgren IM, Lindström LH: CSF levels of HVA and 5-HIAA in drugfree schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res, 1998; 81(2): 101-110
24. Matsuo M, Tasaki R, Kodama H, Hamasaki Y: Screening for Menkes disease using the urine HVA/VMA ratio. J Inherit Metab Dis, 2005; 28(1): 89-93
25. Coccaro EF, Hirsch SL, Stein MA: Plasma homovanillic acid correlates inversely with history of learning problems in healthy volunteer and personality disordered subjects. Psychiatry Res, 2007; 149(1-3): 297-302
26. Castellanos FX, Elia J, Kruesi MJ et al: Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology, 1996; 14(2): 125-137
27. Marín-Valencia, Serrano M, Ormazabal A et al: Biochemical diagnosis of dopaminergic disturbances in paediatric patients: Analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin Biochem, 2008; 41: 1306-1315
28. Van Der Heyden JC, Rotteveel JJ, Wevers RA: Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism. Eur J Paediatr Neurol, 2003; 7(1): 31-37
29. Nishimura K, Hara M: Pathogenetic role of monoamine metabolism in complex febrile seizures. Pediatr Neurol, 1999; 21(2): 553-556
30. Jankovic J, Tintner R: Dystonia and parkinsonizm. Parkinsonism Relat Disord, 2001; 8: 109-121
31. Espino A, Llorens J, Calopa M et al: Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion. Brain Res, 1995; 669: 19-25
32. Engström G, Alling C, Blennow K et al: Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol, 1999; 9(5): 399-405
33. Lawford BR, McD Young R, Noble EP et al: D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder. Eur Neuropsychopharmacol, 2003; 13(5): 313-320
34. Sjögren M, Minthon L, Passant U et al: Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging, 1998; 19(5): 379-384
35. Summers MO, Crisostomo MI, Stepanski EJ: Recent developments in the classification, evaluation, and treatment of insomnia. Chest,2006; 130(1): 276-286
36. Gabis L, Pomeroy J, Andriola MR: Autism and epilepsy: cause, consequence, comorbidity, or coincidence? Epilepsy Behav, 2005; 7(4): 652-656
37. Steyn B, Le Couteurw A: Understanding autism spectrum disorders. Current Paediatrics, 2003; 13: 274-278
38. Anderson GM, Hoshino Y: Neurochemical studies of autism. In: Cohen DJ, Volkmar FR (eds.), Handbook of autism and pervasive developmental disorders. 2nd ed. New York: John Wiley & Sons; 1997; 325-343
39. Ailts J, Ailts D, Bull M: Urinary neurotransmitter testing: myths and misconceptions. NeuroScience, 2007; 1-6
40. Seraidarian P, Seraidarian PI, das Neves Cavalcanti B et al: Urinary levels of catecholamines among individuals with and without sleep bruxism. Sleep Breath, 2009; 13(1): 85-88
41. Grkovic S, Nikolic R, Dordevic M, Stojanov L: Urinary catecholoamine metabolites: capillary gas chromatography method and experience with 12 cases of neuroblastoma. Indian Journal of Clinical Biochemistry, 2005; 20(2): 178-181
42. Hérault J, Martineau J, Perrot-Beaugerie A et al: Lelord G, Muh JP. Investigation of whole blood and urine monoamines in autism. Eur Child Adolesc Psychiatry, 1993; 2(4): 211-220
43. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association, 1994
44. Kuśmierek K, Głowacki R, Bald E: Analysis of urine for cysteine, cysteinylglycine, and homocysteine by high-performance liquid chromatography. Anal Bioanal Chem, 2006; 385(5): 855-860
45. FDA Guidance for Industry Bioanalytical Method Validation, http://www.fda.gov/cder/guidance/4252fnl.pdf
46. Needleman HL: The current status of childhood low-level lead toxicity. Neurotoxicology, 1993; 14(2-3): 161-166
47. Adcock JL, Barnett NW, Costin JW et al: Determination of selected neurotransmitter metabolites Rusing monolithic column chromatography coupled with chemiluminescence detection. Talanta, 2005; 67: 585-589
48. Paul C, Williams KE, Riegel K, Gibbons B: Combining repeated taste exposure and escape prevention: an intervention for the treatment of extreme food selectivity. Appetite, 2007; 49(3): 708-711
49. Mashige F, Ohkubo A, Matsushima Y et al: High-performance liquid chromatographic determination of catecholamine metabolites and 5-hydroxyindoleacetic acid in human urine using a mixed-mode column and an eight-channel electrode electrochemical detector. J Chromatogr B Biomed Appl, 1994; 658(1): 63-68
50. Seegal RF, Brosch KO, Bush B: High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. J Chromatogr, 1986; 377: 131-144
51. Bonfigli AR, Coppa G, Testa R et al: Determination of vanillylmandelic, 5-hydroxyindoleacetic and homovanillic acid in urine by isocratic liquid chromatography. Eur J Clin Chem Clin Biochem, 1997; 35(1): 57-61
52. Manini P, Andreoli R, Cavazzini S et al: Liquid chromatography-electrospray tandem mass spectrometry of acidic monoamine metabolites. J Chromatogr B Biomed Sci Appl, 2000; 744(2): 423-431